Chapter 4

Kidney

(ETKAS and ESP)
## Change record

<table>
<thead>
<tr>
<th>Date</th>
<th>Author</th>
<th>Version</th>
<th>Change reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>03-11-2020</td>
<td>C.M. Tieken</td>
<td>2020.3</td>
<td>Adjustment ESP Hungary and table pending recommendations</td>
</tr>
<tr>
<td>17-09-2020</td>
<td>J. de Boer</td>
<td>2020.2</td>
<td>Textual corrections</td>
</tr>
<tr>
<td>09-01-2020</td>
<td>J. de Boer</td>
<td>9.0</td>
<td>Introduction of the virtual PRA as the only way to define the sensitization status of a patient (R-TTAC01.10)</td>
</tr>
<tr>
<td>05-11-2019</td>
<td>C.M. Tieken</td>
<td>8.2</td>
<td>Adjustment of the ESP in Belgium</td>
</tr>
<tr>
<td>26-09-2019</td>
<td>C.M. Tieken</td>
<td>8.1</td>
<td>Adjustment to the current situation on rescue donors ≥ 65, decision time EA, adjustment recommendation table</td>
</tr>
<tr>
<td>26-03-2019</td>
<td>C.M. Tieken</td>
<td>8.0</td>
<td>4.10.4 adjustment of the calculation of balances</td>
</tr>
<tr>
<td>20-02-2018</td>
<td>C.M. Tieken</td>
<td>7.0</td>
<td>4.3.3. HU have priority in AM, 4.13 adjustment recommendation table</td>
</tr>
<tr>
<td>17-11-2017</td>
<td>C.M. Tieken</td>
<td>6.1</td>
<td>Adjustment 4.3.7</td>
</tr>
<tr>
<td>03-10-2017</td>
<td>C.M. Tieken J. Hagenaars</td>
<td>6.0</td>
<td>General revision manual, adding table pending recommendations, R-KAC01.14 and R-KAC05.14, marginal kidneys</td>
</tr>
<tr>
<td>11-11-2016</td>
<td>C.M. Tieken</td>
<td>5.2</td>
<td>Textual adjustment and skipping the evaluation of ET Med. staff on HU request with the indication of suicide</td>
</tr>
<tr>
<td>28-07-2016</td>
<td>C.M. Tieken</td>
<td>5.1</td>
<td>Outdated screening time adjusted</td>
</tr>
<tr>
<td>26-02-2016</td>
<td>C.M. Tieken</td>
<td>5.0</td>
<td>Frequency table update, adding Belgium waiting time return after living donor transplant</td>
</tr>
<tr>
<td>09-04-2015</td>
<td>C.M. Tieken</td>
<td>4.3</td>
<td>Change name code of conduct in kidney audit procedure</td>
</tr>
<tr>
<td>05-01-2015</td>
<td>J. de Boer</td>
<td>4.2</td>
<td>Revision Table 4.7.1.,</td>
</tr>
<tr>
<td>23-07-2014</td>
<td>C.M. Tieken</td>
<td>4.1</td>
<td>New paragraph(introduction),revision other paragraphs</td>
</tr>
<tr>
<td>03-03-2014</td>
<td>C.M. Tieken</td>
<td>4.0</td>
<td>Revision manual and removal ESDP program</td>
</tr>
<tr>
<td>04-11-2013</td>
<td>J. de Boer</td>
<td>3.2</td>
<td>Erratum calculation Regional balance Austria</td>
</tr>
<tr>
<td>20-06-2013</td>
<td>J. de Boer</td>
<td>3.1</td>
<td>Added Hungary as new member state</td>
</tr>
<tr>
<td>08-03-2013</td>
<td>J. de Boer</td>
<td>3.0</td>
<td>Textual adjustments, NHB→DCD</td>
</tr>
<tr>
<td>31-01-2013</td>
<td>J. de Boer</td>
<td>2.0</td>
<td>Adding: 1.Bonus for patients having donated one of their own kidneys 2. Exception on the no serum-no offer rule, HU patients with entered unacceptable antigens.</td>
</tr>
<tr>
<td>20-06-2012</td>
<td>J. de Boer</td>
<td>1.9</td>
<td>Change policy on donors aged ≥75 years</td>
</tr>
<tr>
<td>Date</td>
<td>Author</td>
<td>Version</td>
<td>Change reference</td>
</tr>
<tr>
<td>--------------------</td>
<td>-------------</td>
<td>---------</td>
<td>----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>23-02-2011</td>
<td>J. de Boer</td>
<td>1.8</td>
<td>Erratum pediatric status: proof of maturation</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Return waiting time after living donor transplant</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Kidney after liver transplant</td>
</tr>
<tr>
<td>26-11-2010</td>
<td>J. de Boer</td>
<td>1.7</td>
<td>Adaptation:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1. HU Audit procedure adapted</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2. pediatric status and pediatric bonus</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>3. definition return of waiting time</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>4. ABO blood group rules</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>5. ESP scheme for Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Adding:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1. Definition of maintenance dialysis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2. Audit procedure proof of maturation</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>3. ESPD allocation scheme</td>
</tr>
<tr>
<td>18-09-2009</td>
<td>J. de Boer</td>
<td>1.6</td>
<td>Simplified overview pediatric bonus</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Priority for Kidney-non renal candidate patients within AM program and regional</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Kidney Exchange Balance Austria added</td>
</tr>
<tr>
<td>23-03-2009</td>
<td>J. de Boer</td>
<td>1.5</td>
<td>Adaptation of point assignment for waiting time and distance</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>according to RKAC01.08</td>
</tr>
<tr>
<td>22-12-2008</td>
<td>J. de Boer</td>
<td>1.4</td>
<td>Correction ABO rules Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Change in HU audit</td>
</tr>
<tr>
<td>17-03-2008</td>
<td>J. de Boer</td>
<td>1.3</td>
<td>Adaptation of definition of a pediatric transplant candidate/ pediatric point</td>
</tr>
<tr>
<td>19-09-2007</td>
<td>J. de Boer</td>
<td>1.2</td>
<td>Adaptation AB0 blood group frequency</td>
</tr>
<tr>
<td>13-08-2007</td>
<td>J. de Boer</td>
<td>1.1</td>
<td>Adding:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1. Croatia Added as Eurotransplant member state</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Adaptation</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1. calculation National Kidney exchange balance</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2. ABO selection ESP and 000 HLA mismatches Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>3. Rules concerning Positive preliminary cross match</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>4. Allocation sequence 000 HLA mismatched patients in case of fully HLA homozygous</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>donors</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>5. Allocation sequence for donors age &lt; 10 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>6. flow charts ETKAS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>7. HLA antigen frequency table</td>
</tr>
<tr>
<td>01-01-2007</td>
<td></td>
<td>1.0</td>
<td>Start of change record</td>
</tr>
</tbody>
</table>

The Eurotransplant Manual contains the rules and regulations for the implementation and specification of national legislation and national guidelines for waiting list management, organ procurement and allocation. It has been prepared with the best of knowledge and the utmost care. In case of discrepancies between the content of this manual and national binding provisions, the following applies:

- Insofar, as provisions about the acceptance of organ patients to the waiting list are concerned, this manual has only an informative character. Only the national provisions which are applicable for the transplant centers are relevant and legally binding.
- For the allocation of organs only the national provisions are legally binding. The display of the allocation provisions in this Manual are based on these legally binding national provisions. As far as necessary, they have been specified by Eurotransplant in this Manual. Deviations from such specifying Eurotransplant provisions cannot be considered as a breach of the national provisions as long as the latter are not violated. Eurotransplant cannot be held liable for a potentially wrongful description in this Manual of procedures, in connection with the organ allocation, as long as the actual allocation follows national provisions.

This Manual is property of Eurotransplant. Reproduction of the Manual, in whole or part, is only permitted with prior permission of Eurotransplant.
## Table of Contents

### 4.1 INTRODUCTION KIDNEY ALLOCATION

4.1.1 General ................................................................................................................. 8
4.1.2 Flowchart kidney allocation .................................................................................. 8

### 4.2 KIDNEY - URGENCY CODES

4.2.1 High urgency (HU) Kidney status ..................................................................... 9
   4.2.1.1 All countries; HU inclusion criteria ................................................................. 9
   4.2.1.2 Change in the clinical situation of a patient with HU status ......................... 9
4.2.2 HU status request ............................................................................................... 9

### 4.3 GENERAL INFORMATION ON THE ALLOCATION OF KIDNEYS

4.3.1 AB0 blood group rules ....................................................................................... 10
   4.3.1.1 AM program ...................................................................................................... 10
   4.3.1.2 ESP, ETKAS ...................................................................................................... 10
4.3.2 Donation after circulatory death (DCD) kidneys ............................................. 10
   4.3.2.1 DCD type II ...................................................................................................... 10
   4.3.2.2 DCD type III .................................................................................................... 10
4.3.3 Acceptable Mismatch (AM) program ................................................................. 11
4.3.4 Eurotransplant Kidney allocation system (ETKAS – donors < 65 years) ....... 11
4.3.5 Eurotransplant Senior Program (ESP - donors ≥ 65 years) ............................. 11
4.3.6 Choice of allocation program in Germany ......................................................... 12
4.3.7 Donors ≤ 5 years and en-bloc procurement ..................................................... 12
   4.3.7.1 Donors ≤ 2 years ............................................................................................. 12
   4.3.7.2 Donors ≥ 2 and ≤ 5 years ................................................................................. 12
4.3.8 Donors aged ≥65 years, logistic reason to start rescue .................................. 12
4.3.9 Donors aged ≥75 years ....................................................................................... 12
4.3.10 Marginal kidneys ............................................................................................... 12
4.3.11 Decision time in the recipient-oriented rescue allocation of kidneys .......... 12
4.3.12 Prospective cross-match .................................................................................. 12
   4.3.12.1 Prospective preliminary cross-match .............................................................. 13
   4.3.12.2 No serum available for preliminary cross-match .......................................... 13
4.3.13 HLA-Typing ...................................................................................................... 13

### 4.4 ETKAS - POINT SCORE SYSTEM

4.4.1 000 MM ............................................................................................................. 13
4.4.2 Point assignment HLA........................................................................................................13
  4.4.2.1 HLA-bonus for pediatric patients.....................................................................................14

4.4.3 Mismatch Probability (MMP)..............................................................................................14

4.4.4 Waiting time.......................................................................................................................14
  4.4.4.1 Pre-emptive patients........................................................................................................14
  4.4.4.2 Return of waiting time after transplantation.................................................................14

4.4.5 Pediatric bonus....................................................................................................................14
  4.4.5.1 Germany.......................................................................................................................14
  4.4.5.2 Other countries .............................................................................................................14

4.4.6 Distance between donor center and transplant center.........................................................15

4.4.7 National and regional Kidney Exchange Balance...............................................................15

4.4.8 High Urgency.....................................................................................................................15

4.4.9 Kidney after other organ transplant....................................................................................15

4.4.10 Bonus for patients having donated one of their own kidneys...........................................15
  4.4.10.1 Deviant national regulations; Germany.........................................................................15

4.5 ETKAS – ALLOCATION ALGORITHMS..........................................................................16

4.5.1 Donors < 16 years old.........................................................................................................16

4.5.2 Flowchart 1 – Donor < 16 years .........................................................................................16

4.5.3 Donors ≥ 16 years and < 65 years of age.........................................................................17

4.5.4 Flowchart 2 – Donor ≥ 16 years and < 65 years ...............................................................17

4.6 ESP ALLOCATION ALGORITHMS (DONOR AGED ≥ 65 YEARS)......................18

4.6.1 Eurotransplant Senior program (ESP)..............................................................................18

4.6.2 Flowchart 3 – Donor ≥ 65 years .......................................................................................18

4.7 BACKGROUND INFORMATION ON THE KIDNEY ALLOCATION.......................19

4.7.1 Definitions..........................................................................................................................19
  4.7.1.1 Maintenance dialysis.....................................................................................................19
  4.7.1.2 Fully homozygous.........................................................................................................19
  4.7.1.3 Fully heterozygous.......................................................................................................19
  4.7.1.4 Full house identical.......................................................................................................19
  4.7.1.5 Zero mismatch identical...............................................................................................19
  4.7.1.6 Zero mismatch compatible............................................................................................19
  4.7.1.7 Outdated screening.......................................................................................................19
  4.7.1.8 Local(ly)....................................................................................................................19
  4.7.1.9 Equivalent-local(ly).....................................................................................................19
  4.7.1.10 Regional(ly).............................................................................................................19
  4.7.1.11 National(ly).............................................................................................................20
  4.7.1.12 International..............................................................................................................20
  4.7.1.13 Export.......................................................................................................................20
  4.7.1.14 Import.......................................................................................................................20
  4.7.1.15 Transplantable (T) ..................................................................................................20
4.8 KIDNEY – HIGH URGENCY REQUEST ........................................... 21

4.8.1 HU status request .................................................................... 21

4.8.2 HU audit ............................................................................. 21
  4.8.2.1 Objection ..................................................................... 21

4.9 GENERAL BACKGROUND INFORMATION ...................................... 21

4.9.1 HLA-Typing .......................................................................... 21
  4.9.1.1 Conversion of HLA-A and –B typing ................................. 21
  4.9.1.2 Conversion of HLA-DR typing ........................................ 22
  4.9.1.3 Calculation of HLA mismatches ..................................... 22

4.9.2 Acceptable Mismatch (AM) program – background information ....... 22
  4.9.2.1 Inclusion criteria .......................................................... 22
  4.9.2.2 Minimum requirements for organ offers ........................... 22
  4.9.2.3 Contact with immunologist from the ETRL ..................... 22
    4.9.2.3.1 Effect of judgment by ETRL immunologist ................. 23

4.9.3 ESP - donors ≥ 65 years - background information ........................ 23
  4.9.3.1 National allocation rules in the ESP .................................. 23
    4.9.3.1.1 Austria ................................................................ 23
    4.9.3.1.2 Germany ............................................................ 23
    4.9.3.1.3 Hungary ............................................................. 23
    4.9.3.1.4 The Netherlands .................................................... 23
    4.9.3.1.5 Croatia, Slovenia .................................................. 23
    4.9.3.1.6 Belgium/Luxembourg ............................................ 23

4.10 ETKAS - POINT SCORE SYSTEM - BACKGROUND INFORMATION .... 24

4.10.1 Mismatch Probability (MMP) detailed information ....................... 24
  4.10.1.1 MMP for 0 or 1 HLA mismatch .................................... 24
  4.10.1.2 Antibody screening .................................................... 24
  4.10.1.3 MMP formulas ......................................................... 24

4.10.2 Waiting time – return waiting time ........................................... 25
  4.10.2.1 Waiting time return after kidney transplant of deceased donor 25
  4.10.2.2 Waiting time return after kidney transplant of a living donor 25
    4.10.2.2.1 Deviant rules Netherlands .................................... 25
  4.10.2.3 Total number of waiting time ....................................... 25

4.10.3 Pediatric bonus - Delivering and auditing proof of maturation (non-Germany) .... 26

4.10.4 National Kidney Exchange Balance – detailed information ........... 26
  4.10.4.1 Deviant rules; Austria Regional Kidney Exchange Balance ........ 27

4.10.5 Kidney after other organ transplant (KAOO)– detailed information ...... 27
  4.10.5.1 Germany ................................................................... 27
  4.10.5.2 Other countries ......................................................... 27

4.11.1 Conversion of split HLA-antigen to broad HLA-antigen .................. 28
4.11.2 HLA antigen frequency ......................................................... 29
4.11.3 German ESP (sub) regions .................................................... 30
4.11 FORMS .................................................................................. 31
4.12 PENDING RECOMMENDATIONS ........................................... 31
### 4.1 Introduction kidney allocation

#### 4.1.1 General

This chapter contains information concerning the allocation of kidneys within Eurotransplant (ET). First, a flowchart of the general kidney allocation is presented. Additionally, kidney allocation related definitions are explained. In the following paragraphs, more information about the urgency codes, blood group rules, acceptable mismatch (AM) program, point score system, the allocation algorithms of the ETKAS and ESP allocation can be found. For general information concerning kidney patient registration or reporting of donors to Eurotransplant, please see Chapters 2 The Recipient and 9 The Donor of the ET Manual respectively. Definitions can be found via the following link Definitions.

#### 4.1.2 Flowchart kidney allocation

The flowchart below shows the general scheme of the kidney allocation.

![Flowchart of kidney allocation](image)

- **Kidney donor**
- **Allocation of the kidney(s) in combination with other organs**
- **Donor < 65 years**
  - **AM program**
  - **ETKAS program**
- **Donor ≥ 65 years**
  - **ESP program**
- **Age of donor**
4.2 Kidney - urgency codes

A patient for a kidney is a person who has an end-stage renal disease. The urgency codes are used to classify patients on the waiting list and to prioritize these patients on the match list. The urgency codes represent the aspects of transplantability, medical urgency and the most recent level of allo-sensitization\(^1\) in ENIS (see Table 1).

<table>
<thead>
<tr>
<th>Urgency codes used in Kidney allocation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urgency code</td>
</tr>
<tr>
<td>--------------</td>
</tr>
<tr>
<td>HU</td>
</tr>
<tr>
<td>T</td>
</tr>
<tr>
<td>I</td>
</tr>
<tr>
<td>NT</td>
</tr>
<tr>
<td>R</td>
</tr>
</tbody>
</table>

Table 1, Urgency codes

4.2.1 High urgency (HU) Kidney status

In specific medical situations a HU status can be requested. Below you will find the inclusion criteria. A different set of HU inclusion criteria are present for Germany and non-German countries.

4.2.1.1 All countries; HU inclusion criteria\(^2\)

- Imminent lack of access for either hemodialysis or peritoneal dialysis.
- Severe bladder problems (hematuria, cystitis etc.) due to kidney graft failure after simultaneous kidney + pancreas transplantation, the pancreas graft is bladder-drained and functioning adequately.

4.2.1.2 Change in the clinical situation of a patient with HU status

If the clinical situation of a patient improves, the transplant center should place the patient in any lower urgency status. Patients in HU status who become (temporarily) not transplantable have to be reported as NT. If these patients become transplantable again, a new HU request has to be sent to Eurotransplant.

4.2.2 HU status request

For more information on the request for HU kidney, please see Kidney – high urgency request.

4.3 General information on the allocation of kidneys

In (Flowchart kidney allocation) the flowchart can be found about the general allocation order. The first step in this figure is that kidneys are offered to patients in need for a combined organ transplant including kidney. These patients will get the offer of the combined organs via the

---

\(^1\) R-TTAC01.10: In order to have a uniform and reliable parameter for sensitization in ET, the v-PRA value (based on the phenotype frequency of the unacceptable mismatches) will replace the %PRA value.

\(^2\) R-KAC01.19 - Indications for high urgent kidney transplantation
leading organ (For further information concerning this subject, please see Chapter 3 Allocation General of the ET Manual). The kidney only allocation can be started if one or both kidneys are still available. If the donor is < 65 years old, the AM + ETKAS match is started. In case of a donor ≥ 65 years old, the ESP match will be generated.

4.3.1 AB0 blood group rules

AB0-incompatible kidney transplants from post mortem donors are not allowed.

4.3.1.1 AM program

<table>
<thead>
<tr>
<th>Donor blood group</th>
<th>Eligible patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>A and AB</td>
</tr>
<tr>
<td>B</td>
<td>B</td>
</tr>
<tr>
<td>AB</td>
<td>AB</td>
</tr>
<tr>
<td>O</td>
<td>B and O</td>
</tr>
</tbody>
</table>

Table 2, Blood group rules in AM program

4.3.1.2 ESP, ETKAS

<table>
<thead>
<tr>
<th>Donor blood group</th>
<th>Eligible patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>A</td>
</tr>
<tr>
<td>B</td>
<td>B</td>
</tr>
<tr>
<td>AB</td>
<td>AB</td>
</tr>
<tr>
<td>O</td>
<td>O</td>
</tr>
</tbody>
</table>

Table 3, Blood group rules ETKAS-ESP program

4.3.2 Donation after circulatory death (DCD) kidneys

4.3.2.1 DCD type II

Kidneys of DCD type II donors are allocated according to the following scheme:

**Donors <65 years (HLA typing must be performed)**
1. 000 MM (national only)
2. Donor center offer
3. Extended allocation (EA) – first line extended (national)
4. Second line rescue (international)

**Donors ≥65 years**
1. Donor center offer
2. Extended allocation (EA) – first line extended (national)
3. First line rescue
4. Second line rescue (international)

4.3.2.2 DCD type III

Kidneys for donation after cardiocirculatory death (DCD) type III are allocated according to the same algorithm as for kidney donation after brain death (DBD) in the countries in which it is legal and ethical allowed.

For further information concerning this subject, please see Chapter 9 of the ET manual.

---

3 R-KAC02.17 - blood group rules in kidney allocation, implemented March 16, 2021
4 R-KAC05.14 – allocation DCD type II; board approval, Jan 2015
4.3.3 Acceptable Mismatch (AM) program

The Acceptable Mismatch (AM) program aims to allocate organs to patients who are immunologically compromised because of current and/or historical HLA-sensitization, to increase their chances on an organ.

The program identifies HLA mismatches that most likely will not result in a positive cross match. The Eurotransplant Reference Laboratory (ERTL) will check the HLA antigens to which the patient has not yet reacted to with allo-antibodies and therefore might be acceptable for the patient. Patient that are included in the AM program will be excluded from other kidney allocation programs.5

Patients selected by this program have priority over ETKAS-selected patients. Within the AM program, patients awaiting a combined kidney-non renal transplant have priority over kidney only patients. Thereafter patients that have HU kidney status will be prioritized above non-HU kidney only patients. For more information see Chapter 10 Histocompatibility and in the background information, see Acceptable Mismatch (AM) program – background information.

4.3.4 Eurotransplant Kidney allocation system (ETKAS – donors < 65 years)

The selection of potential patients is based on AB0 blood group rules. The ranking of these patients is based on age, medical urgency, mismatch probability, HLA-A, -B, -DR matching between donor and patient, waiting time and donor region.

After the AM patients 000 MM patients are ranked on top according of a point score and thereafter other selected potential patients are ranked according of a point score system. The patient with the highest score is ranked on top and receives the first offer. The score is calculated for all patients, including 000-mismatched (MM) patients in order to rank the 000-mismatched patients among each other.

For detailed information of the point score system, see ETKAS - Point score system.
For detailed information of the allocation scheme see ETKAS – allocation algorithms.

4.3.5 Eurotransplant Senior Program (ESP - donors ≥ 65 years)

The aim of the ESP is to decrease the cold ischemic period (CIP) of the kidney. Therefore, the Eurotransplant Senior Program (ESP) allocates kidneys from post-mortem donors ≥ 65 years old to patients of ≥65 years without the use of a donor HLA typing (excl. Netherlands, Belgium/Luxembourg and Hungary; the match in these countries is generated after reporting of the HLA). The patients are selected locally, regionally or national and ranked based on urgency and waiting time (dialysis time). Immunized patients are included in the ESP –match list. In case the donor HLA typing is present before the ESP match is generated, unacceptable antigens are taken into account. In case the organs are not accepted via the normal ESP match list the allocation will be changed to extended allocation followed by second and third line rescue.6

For patients that are eligible for rescue offers of kidneys from donors of 65 years and older the donor profile item “extended allocation ESP” must be set to yes.

For detailed national ESP allocation rules see National allocation rules in the ESP
For detailed information concerning the allocation scheme, see ESP allocation algorithms (Donor aged ≥ 65 years).

5 R-TTAC02.15 - Choice for AM vs ETKAS and,or ESP, implemented March 16, 2021
6 R-KAC02.14 - allocation ESP, kidneys implemented March 16, 2021
4.3.6 Choice of allocation program in Germany

In Germany, patients that are 65 years or older have to choose for either being included in the ESP or the ETKAS program. These programs are mutually exclusive.

4.3.7 Donors ≤ 5 years and en-bloc procurement

4.3.7.1 Donors <2 years

From donors under the age of 2 years the kidneys must be procured en-bloc. It is not mandatory to transplant the kidneys en bloc. It is up to the transplant center to take a decision whether they transplant 1 or 2 kidneys.

4.3.7.2 Donors ≥ 2 and ≤ 5 years

From donors ≥ 2 and ≤ 5 years old it is recommended to procure the kidneys en-bloc. For further information concerning the procurement of the kidneys, please see Chapter 9 The Donor of the ET manual.

4.3.8 Donors aged ≥65 years, logistic reason to start rescue

P-KAC05.19 – Logistic reason to start rescue of kidneys from ESP donors

Rescue allocation of kidneys from donors ≥ 65 years can be started if the organ has not been accepted for any patient within 5 hours after procurement or declined > 5 centers.

4.3.9 Donors aged ≥75 years

Only in case of a rescue allocation for a donor ≥75 years old, the transplant center has the possibility to transplant both kidneys into one patient. In all other cases a single kidney transplant is preferred, but en bloc transplantation might be possible based on the quality of the kidneys.

4.3.10 Marginal kidneys

The following kidneys are marginal kidneys, therefore direct deviation of the normal allocation is acceptable to prevent loss of these organs:

1. A transplanted kidney with a good function which has to be taken out of the living recipient/donor. This kidney can be offered to the center where the living recipient/donor is located.
2. Kidneys of donors ≤ 5 years of age. These organs will first be offered to only one transplant center via the match list. This center can decide to transplant one or both kidneys.

4.3.11 Decision time in the recipient-oriented rescue allocation of kidneys

In non-German countries the decision time in the recipient-oriented rescue allocation is 60 minutes. In Germany the decision time is 30 minutes.9

4.3.12 Prospective cross-match

---

7 P-KAC05.19 – Logistic reason to start rescue of kidneys from ESP donors; board approval, May 2019
8 P-KAC01.17 – Allocation of kidneys of donors ≤ 5 years of age; board approval, Oct. 2017
9 P-KAC02.18 – Decision time in the recipient-oriented rescue allocation (EA) of kidneys, Jan 2019
4.3.12.1 Prospective preliminary cross-match

Donor tissue typing laboratories are obliged to perform cross-matches as ordered by either ET (non-German) countries or the DSO (Germany). In case of a positive preliminary cross-match, no kidney offer will be made to a patient or a conditional offer is withdrawn.

4.3.12.2 No serum available for preliminary cross-match

If a preliminary cross-match cannot be performed because no serum is available, no kidney offer can be made to a patient or the conditional offer is withdrawn, except in case of an immunized (for definitions, see Definitions) HU patient for whom unacceptable antigens are entered into the system.

4.3.13 HLA-Typing

For more information on HLA typing, see HLA-Typing and Chapter 10 Histocompatibility Testing of the ET Manual.

4.4 ETKAS - Point score system

This paragraph will describe information concerning the point score system for generating the match list for kidney patients. For background information on the point score system see For the allocation scheme, ETKAS – allocation algorithms

4.4.1 000 MM

After the AM patients first the patients with a 000-MM are ranked according to their point score.

4.4.2 Point assignment HLA

The number of mismatches on the loci HLA-A, HLA-B and HLA-DR is added according to the following formula:

\[ = 400 \times [1 - (\Sigma \text{ broad HLA-A, -B, split HLA-DR mismatches } / 6)] \]

<table>
<thead>
<tr>
<th>Number of HLA-A, -B, -DR mismatches</th>
<th>Number of points</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>400.00</td>
</tr>
<tr>
<td>1</td>
<td>333.33</td>
</tr>
<tr>
<td>2</td>
<td>266.67</td>
</tr>
<tr>
<td>3</td>
<td>200.00</td>
</tr>
<tr>
<td>4</td>
<td>133.33</td>
</tr>
<tr>
<td>5</td>
<td>66.67</td>
</tr>
<tr>
<td>6</td>
<td>0.00</td>
</tr>
</tbody>
</table>
4.4.2.1 HLA-bonus for pediatric patients

For pediatric patients, the points for HLA-antigen mismatch are doubled (see Pediatric bonus).

4.4.3 Mismatch Probability (MMP)

Mismatch Probability is a calculation of the probability of receiving a kidney offer with 0 and 1 broad HLA-A, -B or split DR mismatches based on 1000 kidneys offered, taking into account AB0 blood group rules and vPRA. Patients receive between 0-100 MMPs. Detailed information, see Mismatch Probability (MMP) detailed information.

4.4.4 Waiting time

Upon registration on the kidney waiting list, the initial date of start of maintenance dialysis (no interruption of dialysis > 90 days) of the patient is counted. For patients that are re-registered the date of re-institution of maintenance dialysis after previous kidney transplantation is counted as the first day for the calculation (start of the waiting time). Per year waiting time, 33.3 points are given (i.e. 0.091 points per day waiting). Waiting time points can be accrued unrestrictedly.

4.4.4.1 Pre-emptive patients

It is possible to register pre-emptive patients (exclusion of Germany) on the active Eurotransplant kidney waiting list. These patients do not receive points for waiting time. Please be aware that there might be different national rules concerning the registration of pre-emptive patients on the waiting list.

4.4.4.2 Return of waiting time after transplantation

For detailed information, see Waiting time – return waiting time.

4.4.5 Pediatric bonus

4.4.5.1 Germany

In Germany, the pediatric bonus is given till 18 years if they fulfill the registration criteria of Germany. At the age of 18 the patient loses the pediatric bonus. There is no maturation status in Germany.

4.4.5.2 Other countries

A transplant candidate is defined pediatric if:
1. Dialysis started before the 16th birthday or
2. Registration on the waiting list was before the 16th birthday and dialysis started before the 17th birthday or
3. Patient is proven to be in maturation.

Each pediatric transplant candidate is assigned a pediatric bonus of 100 points. For pediatric patients the points for HLA-antigen mismatch are doubled. Delivering and auditing proof of maturation, see Pediatric bonus - Delivering and auditing proof of maturation.

10 Richtlinie gemäß § 16 Abs. 1 S. 1 Nrn. 2 u. 5 TPG für die Wartelistenführung und die Organvermittlung zur Nierentransplantation. Published by the Bundesärztekammer (www.baek.de).
4.4.6 Distance between donor center and transplant center

<table>
<thead>
<tr>
<th>Local Equivalent</th>
<th>Austria</th>
<th>Belgium / Luxemburg</th>
<th>Croatia</th>
<th>Germany</th>
<th>Hungary</th>
<th>The Netherlands</th>
<th>Slovenia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>200</td>
<td>200 (also eq)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>100</td>
</tr>
<tr>
<td>Regional</td>
<td></td>
<td></td>
<td></td>
<td>200</td>
<td></td>
<td></td>
<td>100</td>
</tr>
<tr>
<td>National</td>
<td>100</td>
<td>100</td>
<td>300</td>
<td>100</td>
<td>300</td>
<td>300</td>
<td>100</td>
</tr>
</tbody>
</table>

The total amount of points given to national patients is composed from national points plus, if applicable, the local or regional points.

4.4.7 National and regional Kidney Exchange Balance

The following balances are calculated in the point score:
- National Balance Points = (highest import balance – recipient country balance) x 30
- Regional Balance Points = 0.25 x (Austrian National Balance - Regional Balance)

For detailed information, see [National Kidney Exchange Balance – detailed information].

4.4.8 High Urgency

Patients for which the HU status is approved will receive a bonus of 500 points. Please Note: the required HLA mismatch criteria is not taken into account when the patient has the HU status.

4.4.9 Kidney after other organ transplant

In addition to the option of performing a simultaneous other organ-kidney transplant the option of transplanting first the other organ and the kidney at a later time is possible in selected cases (i.e. a kidney-after-other organ transplant). Patients fulfilling the criteria will receive 500 bonus points. Criteria, see 4.10.5

4.4.10 Bonus for patients having donated one of their own kidneys

Patients suffering from end stage renal disease after having donated one of their own kidneys will be granted once-only an allocation bonus of 500 points upon registration on the waiting list. In exceptional cases, upon request of the transplant center, this bonus can be granted a second time. Each request for a repeated bonus should be well motivated and will be evaluated by all ETKAC members.

4.4.10.1 Deviant national regulations; Germany

Granting this bonus has not yet been accepted by the German national authorities.

11 Please note the Regional Balance Points can be negative, which means a deduction of the total pointscore.
4.5 ETKAS – allocation algorithms

4.5.1 Donors < 16 years old

First, to AM program patients (pediatric & adult)
then, to zero (000) HLA-A, -B and -DR mismatch patients (pediatric & adult)
in case of a HLA fully homozygous donor patients are ranked from fully homozygous
to fully heterozygous. Within each group, patients are ranked according to their point score.
then, to patients having the pediatric status, ranked according to their point score.
then, to all other I, T and HU patients ranked according to their point score.

4.5.2 Flowchart 1 – Donor < 16 years

![Flowchart](image)
4.5.3 Donors ≥ 16 years and < 65 years of age

First, to AM program patients then, to zero (000) HLA-A, -B and -DR mismatch patients in case of a HLA fully homozygous donor (see Fully homozygous): patients are ranked from fully homozygous to fully heterozygous. Within each group patients are ranked according to their point score.
then, to I, T and HU patients ranked according to their point score.

4.5.4 Flowchart 2 – Donor ≥ 16 years and < 65 years
4.6 ESP allocation algorithms (Donor aged ≥ 65 years)

4.6.1 Eurotransplant Senior program (ESP)

First, a patient oriented allocation to local, regional or national patients aged ≥ 65 years; first HU then KAOO followed by elective ranked on waiting time (=dialysis time):

- Austria → Locally or equivalent
- Germany → First subregion (see German ESP (sub) regions) then other subregions within that coordination region in Germany
- Hungary → Region of the donor before nationally
- The Netherlands, Croatia and Slovenia → Nationally
- Belgium/Luxembourg → Local center of the donor before national

Then, according to rescue allocation:
 pierwszy Extended allocation followed by second and third line rescue.

4.6.2 Flowchart 3 – Donor ≥ 65 years
4.7 Background information on the kidney allocation

4.7.1 Definitions

Below, definitions related to the kidney allocation can be found. For the definitions concerning the urgency codes, please see Kidney - urgency codes urgency codes.

4.7.1.1 Maintenance dialysis

The dialysis has not been interrupted for more than 90 days.

4.7.1.2 Fully homozygous

Inheritance of two identical HLA antigens at each polymorphic locus.

4.7.1.3 Fully heterozygous

Inheritance of two different HLA antigens at each polymorphic locus.

4.7.1.4 Full house identical

The donor and patient have both 6 different HLA antigens of which all antigens are the same, e.g.:

Donor typing A1 A2 B7 B8 DR1 DR13
Patient typing A1 A2 B7 B8 DR1 DR13

4.7.1.5 Zero mismatch identical

The donor and patient have the same amount of HLA antigens but less than 6, of which all antigens are the same, e.g.:

Donor typing A1 A2 B7 B8 DR1 -
Patient typing A1 A2 B7 B8 DR1 -

4.7.1.6 Zero mismatch compatible

The donor has less HLA antigens than the patient, but the patient has all of the donor HLA antigens, e.g.:

Donor typing A1 - B7 B8 DR1 -
Patient typing A1 A2 B7 B8 DR1 DR13

4.7.1.7 Outdated screening

Outdated screenings are those HLA-specific antibody screening results that are older than 180 days at time of matching. Patients with outdated screening are not selected in matching procedures.

4.7.1.8 Local(ly)

Patients from the same center as the donor center.

4.7.1.9 Equivalent-local(ly)

Equivalent to a local status are patients from collaborating transplant programs (regional or national).

4.7.1.10 Regional(ly)

One or more transplant centers in the same region of the donor center. Such a region can consist of one or more transplant programs. (e.g. In Germany the seven regions
are consistent with the seven donor regions defined by the organ procurement organization Deutsche Stiftung Organtransplantation (DSO)).

4.7.1.11 National(ly)

All transplant programs in the same country (but outside the region) of the donor center.

4.7.1.12 International

All transplant programs outside the country of the donor center.

4.7.1.13 Export

i.e. a negative balance, is defined as: kidneys procured in a country > kidneys transplanted in that country.

4.7.1.14 Import

i.e. a positive balance, is defined as: kidneys procured in a country < kidneys transplanted in that country.

4.7.1.15 Transplantable (T)

Elective patients who are transplantable and have a vPRA of 0%.

4.7.1.16 High Urgency (HU) patients

Patients who are according to the criteria and/or accepted by the international ETKAC audit approved for a high urgent status.

4.7.1.17 Immunized (I) patients

Patients who are transplantable and have a vPRA of >0%.

4.7.1.18 Not Transplantable (NT) patients

Patients temporarily not transplantable should be placed in urgency NT.

4.7.1.19 Removed (Urgency R)

A patient should be removed (Urgency R) from the waiting list if the patient is deteriorated beyond transplantability.

4.7.1.20 Pre-emptive patients

Patients that are listed on the waiting list but have not yet started their dialysis.
4.8    Kidney – high urgency request

4.8.1    HU status request

A remote center cannot assign a HU status in ENIS, but they have to send a request to Eurotransplant. For requesting a HU status for a patient, the form “Kidney High Urgency form” should be used (see Forms at www.eurotransplant.org). Please be aware that only HU requests are taken into account in case the patient is placed on an active urgency status. The Urgency form must be send to Eurotransplant (urgency@eurotransplant.org) and has to be accompanied by an English letter of motivation and additional medical reports. Depending on the HU inclusion criterion related to the patient, a report from one or two competent specialist(s) in the field of the indication must be included (see form). Additionally, information concerning a consideration of a living donor should be added.

4.8.2    HU audit

The HU request with a standard indication will initially be evaluated by two members of the Eurotransplant Kidney Advisory committee. In case of a split decision, a third member of the Eurotransplant Kidney Advisory committee will be consulted for a final judgment. Only after approval, the HU status will be granted and the urgency will be changed in ENIS by the Eurotransplant waiting list officer. In case of the indication "other" the request is sent to all auditors and the request is accepted when 2/3 of the eligible members supports the request. Doctors involved in the audit procedure should follow the “Kidney audit procedure” which is published on the ET member site (see library → manuals → Eurotransplant manual → kidney audit procedure).

4.8.2.1    Objection

If the HU request is declined by the audit and the requesting center does not agree with the auditors' decision, only one objection can be send. The requesting center should indicate that the auditors overlooked information or provide additional information that is of importance for the decision of the auditors. The objection has to be submitted to Eurotransplant within 5 working days after the initial decline of the request. The objection letter should be written in English and also summarizes other information (e.g. letters of specialists). The objection will be to the ETKAC for mail voting.

4.9    General background information

4.9.1    HLA-Typing

The HLA match program is only based on the HLA-A, -B and -DR loci. The HLA-C and -DQ antigens, as well as the public antigens of the HLA-B and -DR loci are disregarded from HLA mismatch calculation program.

4.9.1.1    Conversion of HLA-A and –B typing

The HLA broad match phenotype reduction program converts the HLA-A and -B from split HLA-antigen to broad HLA-antigen for matching the donor with the patients (see Conversion of split HLA-antigen to broad HLA-antigen).
4.9.1.2 Conversion of HLA-DR typing

- If a donor with HLA-DR broad antigens is reported to ET without splits, patients will be selected on broad antigen level;
- If a donor with HLA-DR split antigens is reported to ET, patients will be selected on split antigen level. The only exclusion to this rule concerns split antigens DR17/DR18, because they are difficult to distinguish. Donors with HLA-DR 17 or 18 antigens will be matched on broad DR3 antigen level.

4.9.1.3 Calculation of HLA mismatches

The HLA mismatch program calculates HLA-antigen mismatches for HLA-A and -B based on broad antigens only. HLA-antigen mismatches for HLA-DR are calculated based on split HLA antigens.

Mismatches are defined as donor HLA-antigens that are different from the patients HLA-antigens. The converted HLA-typing is only accepted by the HLA-mismatch calculation program in the presence of at least 1 HLA-antigen on each of the three HLA-loci, HLA-A, HLA-B and HLA-DR. For HLA-A and --B, the broad is leading. For HLA-DR, the split is leading.

In case only 1 HLA-antigen is identified (on the A-, B- or DR-locus), the donor or the patient is assumed to be ‘homozygous’ for that locus (i.e. homologous chromosomes are presumed to code for identical antigens at that locus).

Calculation for homozygous locus of a donor:

Donor typing A1
Patient typing A28 A2
In this case only 1 mismatch is calculated.

In case there are 2 identical antigens on one locus, so only on A-, B- or DR-locus, only 1 mismatch is calculated

Calculation for 2 identical antigens on 1 locus of a donor:

Donor typing A9 A9
Patient typing A28 A2
Calculation: Only 1 mismatch is calculated

4.9.2 Acceptable Mismatch (AM) program – background information

For more information, see Chapter 10 Histocompatibility Testing in the ET Manual.

4.9.2.1 Inclusion criteria

The criteria can be found in Chapter 10 Histocompatibility (§ 10.3) in the ET Manual.

4.9.2.2 Minimum requirements for organ offers

The AM program will run for every ETKAS match of a post-mortem kidney donor with a known HLA typing. The program selects potentially cross-match negative AM patients.

4.9.2.3 Contact with immunologist from the ETRL

All eligible AM-patients are presented to and discussed with an ETRL immunologist prior to a kidney offer.
4.9.2.3.1 Effect of judgment by ETRL immunologist

In case an immunized patient is selected through:
- The AM program: The judgment of the ETRL immunologist is binding. If the judgment is negative, then no offer is made for this patient. If the judgment is positive, an offer is made for this patient. No prospective cross match is performed.

4.9.3 ESP - donors ≥ 65 years - background information

4.9.3.1 National allocation rules in the ESP

4.9.3.1.1 Austria

In Austria kidneys from ESP donors are allocated to ESP patients from the reporting center's local waiting list (=donor or equivalent center).

4.9.3.1.2 Germany

In Germany, kidneys from ESP donors are allocated to ESP patients from the corresponding region. These regions are defined by the organ procurement organization Deutsche Stiftung Organtransplantation (DSO) (German ESP (sub) regions). Kidneys from ESP donors are first allocated to ESP patients registered within the same sub-region as the donor and then to ESP patients registered within the other sub-regions within that coordination region in Germany.

4.9.3.1.3 Hungary

In Hungary, the ESP match can only be generated in case the HLA of the donor is known. Kidneys from ESP donors are first allocated to local ESP patients registered within the same region (= donor center, HBSTP, HDBTP, HSZTP or HPCTP) as the donor and then to ESP patients registered nationally.

4.9.3.1.4 The Netherlands,

In the Netherlands, the ESP match can only be generated in case the HLA of the donor is known. The kidneys from ESP donors are allocated to ESP patients according to the national waiting list.

4.9.3.1.5 Croatia, Slovenia

In the Croatia and Slovenia, kidneys from ESP donors are allocated to ESP patients according to the national waiting list.

4.9.3.1.6 Belgium/Luxembourg

The ESP match can only be generated in case the HLA (only for Belgium) of the donor is known. In Belgium, kidneys from ESP donors are first allocated to local ESP patients (= donor center) as the donor and then to ESP patients registered nationally.
ETKAS - Point score system - background information

This paragraph will describe detailed information concerning the point score system for generating the match list for kidney patients. For the allocation scheme, see ETKAS – allocation algorithms.

Mismatch Probability (MMP) detailed information

Mismatch Probability is a calculation of the probability of receiving a kidney offer with 0 and 1 broad HLA-A, -B or split DR mismatches based on 1000 kidneys offered, taking into account AB0 blood group rules and vPRA. Patients receive between 0-100 MMPs.

4.10.1.1 MMP for 0 or 1 HLA mismatch

The broad/split HLA-antigen frequencies, necessary for the calculation of the 0 and 1 HLA MMP, have been calculated on the ETRL Database (HLA antigen frequency).

The MMP for 0 and 1 HLA is determined at the moment of listing on the kidney waiting list. The lower the calculated value for 0 + 1 HLA-MMP (MMP0 + MMP1), the higher the chance of finding a donor with 0 or 1 HLA-mismatches within the Eurotransplant pool.

4.10.1.2 Antibody screening

The antibody screening is recently entered in ENIS and must not be outdated (see Outdated screening). Screenings should be updated every 180 days. If a possible sensitization can take place between regular antibody screening dates, additional antibody screenings should be performed according to the ETRL guidelines.

A higher vPRA indicates a lower chance of finding a donor with a negative cross-match.

4.10.1.3 MMP formulas

All variables are equal to the broad HLA-A and –B and split HLA-DR frequencies in

\[
\text{MMP} = 100 \times (1-\left(\frac{\text{match frequency} \times (1-v\text{PRA}/100)}{\text{MMP0} + \text{MMP1}}\right))^{1000}
\]

\[
\text{MMP0} = (a_1+a_2)^2 \times (b_1+b_2)^2 \times (dr_1+dr_2)^2
\]

\[
\text{MMP1} = \text{MMP0} \times \left(\frac{((2*(a_1+a_2)^2*(1-a_1-a_2)) - a_1^2 - a_2^2 + \sum (\text{all HLA-A Ag frequencies}^2)) / ((a_1+a_2)^2)+((2*(b_1+b_2)^2*(1-b_1-b_2)) - b_1^2 - b_2^2 + \sum (\text{all HLA-B Ag frequencies}^2)) / ((b_1+b_2)^2)+((2*(dr_1+dr_2)^2*(1-dr_1-dr_2)) - dr_1^2 - dr_2^2 + \sum (\text{all HLA-DR Ag frequencies}^2)) / ((dr_1+dr_2)^2))}{\text{MMP0}}\right)
\]

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Frequency of</th>
</tr>
</thead>
<tbody>
<tr>
<td>a1</td>
<td>1&lt;sup&gt;st&lt;/sup&gt; HLA-A antigen</td>
</tr>
<tr>
<td>a2</td>
<td>2&lt;sup&gt;nd&lt;/sup&gt; HLA-A antigen</td>
</tr>
<tr>
<td>b1</td>
<td>1&lt;sup&gt;st&lt;/sup&gt; HLA-B antigen</td>
</tr>
<tr>
<td>b2</td>
<td>2&lt;sup&gt;nd&lt;/sup&gt; HLA-B antigen</td>
</tr>
<tr>
<td>dr1</td>
<td>1&lt;sup&gt;st&lt;/sup&gt; HLA-DR antigen</td>
</tr>
<tr>
<td>dr2</td>
<td>2&lt;sup&gt;nd&lt;/sup&gt; HLA-DR antigen</td>
</tr>
</tbody>
</table>

Parameters a1 - dr2 are derived from the match HLA-typing used for the calculation of the HLA-mismatches.
4.10.2 Waiting time – return waiting time

4.10.2.1 Waiting time return after kidney transplant of deceased donor\textsuperscript{12}

Return of waiting time will be granted in case a recipient requires maintenance of dialysis within 1 year after the kidney transplantation. The percentage of waiting time points will differ dependent on the date the maintenance of dialysis is started in relation to the transplant date.

- 100% waiting time return if maintenance of dialysis starts 0 to 91 days after the kidney transplant;
- 75% waiting time return if maintenance of dialysis starts 92 to 183 days after the kidney transplant;
- 50% waiting time return if maintenance of dialysis starts 184 to 275 days after the kidney transplant;
- 25% waiting time return if maintenance of dialysis starts 276 to 365 days after the kidney transplant.

Patients that require maintenance of dialysis exceeding 1 year after the kidney transplant do not receive any return of waiting time.

The waiting time return will be calculated automatic in case of entering or changing date of (re)institution of dialysis.

4.10.2.2 Waiting time return after kidney transplant of a living donor\textsuperscript{13}

A recipient who is re-registered for a kidney transplant with one or more immediate previous living donor kidney transplantations having failed, requiring maintenance dialysis, is eligible for the return of 100% of the waiting time.

The waiting time return will be calculated automatic in case of entering or changing date of (re)institution of dialysis.

4.10.2.2.1 Deviant rules Netherlands

In the Netherlands a patient that was transplanted with a kidney of an altruistic donor the patient is only qualifies for the rules of waiting time return after kidney transplant of deceased donor.

4.10.2.3 Total number of waiting time

The amount of waiting time equals the number of days from the date of

- Start of dialysis and no previous transplant, or Re-institution of dialysis after the last successful transplant.
- Number of waiting time return based on the rules described in 4.10.2 Waiting time – return waiting time.

\textsuperscript{12} R-KAC03.17 - return waiting time, implemented March 16, 2021

\textsuperscript{13} R-KAC03.10 – waiting time return after living transplantation, implemented March 16, 2021
4.10.3 Pediatric bonus - Delivering and auditing proof of maturation (non-Germany)

A transplant center must send a completed Kidney patient in maturation form including a report from a competent radiologist or pediatric endocrinologist on an X-ray of the left hand (see Forms at www.eurotransplant.org). This report must not be older than 3 months at time of “proof of maturation” was requested. The request will be evaluated by two members of the ETKAC. In case there is no unanimous decision, a third member of the ETKAC will be consulted for a final decision. Proof of maturation should be only requested when the onset of maintenance dialysis is after the 17th birthday or the patient is registered on the kidney waiting list after the 16th birthday and not yet being on dialysis.

After the proof of maturation has been accepted, the pediatric status is granted. The status is granted until:
1. The first successful transplant, in case the patient is on maintenance dialysis.
2. The first successful transplant, in case the maintenance dialysis starts within the first year after registration on the waiting list.
3. For 1 year calculated from date of registration on the waiting list, in case the patient is not on maintenance dialysis.

The pediatric status can be re-installed when the patient is still proven to be in maturation at time of onset of maintenance dialysis. The pediatric status will then be granted until the first successful transplant.

4.10.4 National Kidney Exchange Balance – detailed information

As of April 1, 2019 the balance in the ETKAS system will be calculated as according to the following policy:

P-KAC06.17 – Donor categories and balance calculation

Kidneys from deceased donors are classified according to donor age categories;
1. Donor age 0-15 years;
2. Donor age 16-49 years;
3. Donor age 50-64 years;
4. Donor age ≥65 years.

These categories will be used in the calculation of the national balances to be used for the balancing factor in ETKAS. The balances increase over time starting at 0 on April 1, 2019.

Once every day, as of April 1, 2019, the difference between the number of kidneys procured, exchanged between each ET country and transplanted, is calculated.

No immediate compensation exists for exchanging kidneys together with non-renal organ(s) from one donor for transplantation into one patient; however, the calculation of kidneys exchanged includes kidneys exchanged together with non-renal organs.

National Balance Points:
1. donor age 0-15 = (highest import balance donor age 0-15 – recipient country balance donor age 0-15) x 30
2. donor age 16-49 = (highest import balance donor age 16-49 – recipient country

---

14 P-KAC06.17- Donor categories and balance calculation; Board approval Oct. 2018
15 Belgium and Luxemburg are considered as one country
balance donor age 16-49) x 30
3. donor age 50-64 = (highest import balance donor age 50-64 – recipient country balance donor age 50-64) x 30

4.10.4.1 Deviant rules; Austria Regional Kidney Exchange Balance

In addition to the National Kidney Exchange Balance, the difference between the number of kidneys procured and exchanged for transplantation between each Austrian center/region and all other (including Austrian) ET centers/regions over the preceding 365 days is calculated once every day.

In case of an Austrian donor, patients from the Austrian centers/regions receive additional balance points according to the following formula:

Regional Balance Points\(^{16}\) = 0.25\(x\) (Austrian National Balance - Regional Balance)

4.10.5 Kidney after other organ transplant (KAOO)-- detailed information

4.10.5.1 Germany\(^{17}\)

Patients are eligible for a KAOO bonus in case the patient have chronic dialysis that starts before the other transplant and is ongoing after the other organ is transplanted. Patients did not have to be on the waiting list before the other organ is transplanted. The KAOO bonus is not valid after transplantation of a pancreas.

If the patient fulfils the criteria, 500 bonus points are automatically given as of 90 days after the other organ transplantation until the first kidney transplantation.

4.10.5.2 Other countries\(^{18}\)

For other countries the patient will automatically receive the bonus points if one of the following criteria is met:

1. The patient is listed on the kidney waiting list before other transplant and dialysis is required after the other organ transplant between 90-360 days,
2. The patient was not listed on the kidney waiting list before other transplant
   a. dialysis was required at least 6 weeks before other transplant
   b. dialysis is required after the other organ transplant between 90-360 days.

If the patient fulfills the criteria, 500 bonus points are automatically given as of 90 days after the other organ transplantation until the first kidney transplantation

If the patient did not automatic receive the bonus points and the transplant center is of the opinion the patient fulfills the criteria an audit on the case can be requested.

---

\(^{16}\) Please note the Regional Balance Points can be negative, which means a deduction of the total point score

\(^{17}\) Richtlinie gemäß § 16 Abs. 1 S. 1 Nrn. 2 u. 5 TPG für die Wartelistenführung und die Organvermittlung zur Nierentransplantation. Published by the Bundesärztekammer (www.baek.de).

\(^{18}\) R-KAC03.16 - KAOO bonus, implemented March 16, 2021
### 4.11.1 Conversion of split HLA-antigen to broad HLA-antigen

<table>
<thead>
<tr>
<th></th>
<th>A9</th>
<th>A10</th>
<th>A19</th>
<th>A28</th>
<th>A68</th>
<th>A69</th>
</tr>
</thead>
<tbody>
<tr>
<td>A23</td>
<td>B51</td>
<td>B52</td>
<td>DR15</td>
<td>DR2</td>
<td>DR5</td>
<td>DR6</td>
</tr>
<tr>
<td>A24</td>
<td>B5</td>
<td>DR16</td>
<td>Cw9</td>
<td>Cw3</td>
<td>DQ5</td>
<td>DQ3</td>
</tr>
<tr>
<td>A25</td>
<td>B44</td>
<td>B12</td>
<td>DR3</td>
<td></td>
<td>DQ7</td>
<td></td>
</tr>
<tr>
<td>A26</td>
<td>B45</td>
<td>B14</td>
<td></td>
<td></td>
<td>DQ8</td>
<td></td>
</tr>
<tr>
<td>A34</td>
<td>B46</td>
<td>B15</td>
<td></td>
<td></td>
<td>DQ9</td>
<td></td>
</tr>
<tr>
<td>A66</td>
<td>B62</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A29</td>
<td>B63</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A30</td>
<td>B64</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A31</td>
<td>B65</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A32</td>
<td>B66</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A33</td>
<td>B67</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A74</td>
<td>B68</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A68</td>
<td>B69</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A69</td>
<td>B70</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### 4.11.2 HLA antigen frequency

HLA gen frequencies 2014 excl. HLA-A-B splits

<table>
<thead>
<tr>
<th>HLA-A</th>
<th>2014</th>
<th>HLA-B</th>
<th>2014</th>
<th>HLA-DR</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>A1</td>
<td>0.1534</td>
<td>B5</td>
<td>0.0738</td>
<td>DR1</td>
<td>0.1151</td>
</tr>
<tr>
<td>A2</td>
<td>0.3007</td>
<td>B7</td>
<td>0.1227</td>
<td>DR2</td>
<td>0.1645</td>
</tr>
<tr>
<td>A3</td>
<td>0.1490</td>
<td>B8</td>
<td>0.1025</td>
<td>DR15</td>
<td>0.1277</td>
</tr>
<tr>
<td>A9</td>
<td>0.1138</td>
<td>B12</td>
<td>0.1217</td>
<td>DR16</td>
<td>0.0368</td>
</tr>
<tr>
<td>A10</td>
<td>0.0642</td>
<td>B13</td>
<td>0.0322</td>
<td>DR3</td>
<td>0.1114</td>
</tr>
<tr>
<td>A11</td>
<td>0.0555</td>
<td>B14</td>
<td>0.0236</td>
<td>DR17</td>
<td>0.1112</td>
</tr>
<tr>
<td>A19</td>
<td>0.1195</td>
<td>B15</td>
<td>0.0758</td>
<td>DR18</td>
<td>0.0002</td>
</tr>
<tr>
<td>A28</td>
<td>0.0441</td>
<td>B70</td>
<td>0.0023</td>
<td>DR4</td>
<td>0.1328</td>
</tr>
<tr>
<td>A36</td>
<td>0.0001</td>
<td>B16</td>
<td>0.0454</td>
<td>DR5</td>
<td>0.1463</td>
</tr>
<tr>
<td>A43</td>
<td>0.0001</td>
<td>B17</td>
<td>0.0453</td>
<td>DR11</td>
<td>0.1261</td>
</tr>
<tr>
<td>A203</td>
<td>0.0001</td>
<td>B18</td>
<td>0.0540</td>
<td>DR12</td>
<td>0.0202</td>
</tr>
<tr>
<td>A210</td>
<td>0.0001</td>
<td>B21</td>
<td>0.0232</td>
<td>DR6</td>
<td>0.1639</td>
</tr>
<tr>
<td>A80</td>
<td>0.0001</td>
<td>B22</td>
<td>0.0252</td>
<td>DR13</td>
<td>0.1314</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B27</td>
<td>0.0483</td>
<td>DR14</td>
<td>0.0325</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B35</td>
<td>0.1027</td>
<td>DR7</td>
<td>0.1164</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B37</td>
<td>0.0140</td>
<td>DR8</td>
<td>0.0312</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B40</td>
<td>0.0684</td>
<td>DR9</td>
<td>0.0087</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B41</td>
<td>0.0111</td>
<td>DR10</td>
<td>0.0096</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B42</td>
<td>0.0004</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>B46</td>
<td>0.0002</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>B47</td>
<td>0.0034</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>B48</td>
<td>0.0008</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>B53</td>
<td>0.0027</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>B59</td>
<td>0.0001</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>B67</td>
<td>0.0002</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>B73</td>
<td>0.0002</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>B703</td>
<td>0.0001</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>B78</td>
<td>0.0002</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>B81</td>
<td>0.0001</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>B2708</td>
<td>0.0001</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>B82</td>
<td>0.0001</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>B83</td>
<td>0.0001</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### 4.11.3 German ESP (sub) regions

<table>
<thead>
<tr>
<th>Coordinating region</th>
<th>ESP sub region</th>
<th>Transplant centers</th>
<th>ET center code</th>
</tr>
</thead>
<tbody>
<tr>
<td>GBWOR</td>
<td>OZ Stuttgart</td>
<td>Heidelberg, Mannheim, Stuttgart, Tübingen</td>
<td>GHBTP, GMATP, GSTTP, GTUTP</td>
</tr>
<tr>
<td></td>
<td>OS Freiburg</td>
<td>Freiburg</td>
<td>GFRTP</td>
</tr>
<tr>
<td>GBYOR</td>
<td>OZ München</td>
<td>Augsburg, München, Rechts der Isar, München, Grosshadern, Regensburg</td>
<td>GAUTP, GMLHTP, GMLTP, GRBTP</td>
</tr>
<tr>
<td></td>
<td>OS Erlangen</td>
<td>Nürnberg, Würzburg</td>
<td>GNBTP, GWZTP</td>
</tr>
<tr>
<td>GMIOR</td>
<td>OZ Mainz</td>
<td>Frankfurt am Main, Mainz</td>
<td>GMFMTP, GMZTP</td>
</tr>
<tr>
<td></td>
<td>OS Homburg</td>
<td>Homburg-Saar, Kaiserslautern</td>
<td>GHSTP, GKSTP</td>
</tr>
<tr>
<td></td>
<td>OS Marburg</td>
<td>Fulda, Giessen, Marburg</td>
<td>GFDTP, GGIIP, GMRTP</td>
</tr>
<tr>
<td>GNDOR</td>
<td>OZ Hannover</td>
<td>Bremen, Hannover, Hannoversch-Münden</td>
<td>GBMTP, GHOTP, GHMTP</td>
</tr>
<tr>
<td></td>
<td>OS Hamburg</td>
<td>Hamburg, Kiel, Lübeck</td>
<td>GHGTP, GKIIP, GLUTP</td>
</tr>
<tr>
<td>GNOOR</td>
<td>OZ Berlin</td>
<td>Berlin, UK B.-Franklin, Berlin, Charité</td>
<td>GBETP, GBCTP</td>
</tr>
<tr>
<td></td>
<td>OS Rostock</td>
<td>Rostock</td>
<td>GROTP</td>
</tr>
<tr>
<td>GNWOR</td>
<td>OZ Düsseldorf</td>
<td>Bochum, Düsseldorf, Essen</td>
<td>GBBTP, GDUTP, GESTP</td>
</tr>
<tr>
<td></td>
<td>OS Köln-Bonn</td>
<td>Aachen, Bonn, Köln, Lindenthal, Köln, Merheim</td>
<td>GAKTP, GBOTP, GKLTP, GKMTP</td>
</tr>
<tr>
<td></td>
<td>OS Münster</td>
<td>Münster</td>
<td>GMNTP</td>
</tr>
<tr>
<td>GOSOR</td>
<td>OZ Leipzig</td>
<td>Dresden, Halle, Jena, Leipzig</td>
<td>GDRTP, GHATP, GJETP, GLPTP</td>
</tr>
</tbody>
</table>
### 4.11 Forms

All forms can be found and downloaded from the section 'Forms' of the Library of the member site at [www.eurotransplant.org](http://www.eurotransplant.org).

### 4.12 Pending recommendations

<table>
<thead>
<tr>
<th>Number</th>
<th>Description</th>
<th>Board approval</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>R-KAC03.14</td>
<td>Interruption of dialysis</td>
<td>Jan 2015</td>
<td>Declined in Germany, will be implemented in the countries that accepted the recommendation</td>
</tr>
<tr>
<td>R-KAC04.16</td>
<td>Regulation for transplantation after a positive cross match result</td>
<td>Jan 2016</td>
<td>Pending authorization Germany</td>
</tr>
<tr>
<td>R-KAC04.17</td>
<td>Pediatric waiting list registration</td>
<td>Oct. 2017</td>
<td>rules are under discussion. Germany already implemented rules on pediatric.</td>
</tr>
<tr>
<td>P-KAC02.18</td>
<td>Decision time in the EA of kidneys</td>
<td>Oct. 2018</td>
<td>Implemented Non-German countries, Pending authorization Germany</td>
</tr>
<tr>
<td>R-KAC01.20</td>
<td>Mandatory recipient items</td>
<td>Nov. 2020</td>
<td></td>
</tr>
<tr>
<td>R-KAC02.20</td>
<td>Compensation via audit procedure in special cases</td>
<td>Nov. 2020</td>
<td></td>
</tr>
<tr>
<td>R-KAC02.20</td>
<td>Exclusion of AM and immunized patients from EA and rescue allocation</td>
<td>Nov. 2020</td>
<td></td>
</tr>
</tbody>
</table>